5-amino-1MQ 10mg Canada

Technical Specifications

Compound Name: 5-amino-1-methylquinolinium (5-amino-1MQ)
Quantity: 10mg per vial
Format: Lyophilized or crystalline powder (batch dependent)
Purity Standard: ≥98% (HPLC, batch dependent)
Chemical Class: Nicotinamide N-methyltransferase (NNMT) inhibitor (research classification)
Research Classification: Investigational compound – laboratory research use only

5-amino-1MQ 10mg Canada is supplied as a research-grade small molecule intended exclusively for laboratory and analytical applications. Each vial contains 10 milligrams of the compound prepared under controlled handling standards appropriate for chemical research materials.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada.

Research Overview

5-amino-1MQ is a synthetic small molecule studied primarily in metabolic and enzymatic research contexts. It is frequently cited in the scientific literature as an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in methylation pathways and cellular energy regulation.

Research involving 5-amino-1MQ 10mg Canada generally focuses on enzyme modulation, intracellular metabolism, and adipocyte signalling models. NNMT has been examined in studies exploring its role in nicotinamide metabolism, NAD+ pathway dynamics, and methyl donor utilization.

In laboratory settings, NNMT inhibition is evaluated to understand its impact on cellular metabolic processes better. 5-amino-1MQ has been used in preclinical experimental systems to investigate interactions among biochemical pathways and gene-expression responses under controlled conditions.

All discussion of biological effects relates strictly to investigational research contexts. 5-amino-1MQ 10mg Canada is supplied for analytical and laboratory study only.

Mechanism Overview

5-amino-1MQ is structurally related to quinolinium compounds and functions in research models as a selective inhibitor of the NNMT enzyme. NNMT catalyzes the methylation of nicotinamide using S-adenosylmethionine (SAM) as a methyl donor, producing 1-methylnicotinamide and S-adenosylhomocysteine.

In laboratory investigations, NNMT inhibition by compounds such as 5-amino-1MQ is studied to assess changes in intracellular nicotinamide availability, NAD+ metabolism, and methylation balance. Researchers analyze downstream effects on energy-regulatory pathways and adipocyte metabolism in cell culture and animal models.

5-amino-1MQ 10mg Canada is commonly evaluated for binding affinity, enzyme selectivity, and dose-response characteristics in controlled experimental systems. Its mechanism of action, as described in peer-reviewed literature, remains confined to biochemical and preclinical research findings.

Mechanistic descriptions do not imply approved therapeutic application.

Clinical Development Context

To date, 5-amino-1MQ has primarily been studied in preclinical research environments. Animal models and in vitro experiments have explored its potential influence on metabolic pathways through NNMT inhibition.

Early-stage investigative work has examined pharmacokinetic characteristics and metabolic biomarker changes in controlled research settings. However, 5-amino-1MQ 10mg, supplied in research format, reflects a laboratory compound profile rather than an authorized pharmaceutical product.

There is no Health Canada approval for 5-amino-1MQ as a prescription medication or consumer health product. Its presence in research supply settings corresponds to ongoing scientific interest in NNMT-related metabolic research.

Regulatory Status in Canada

Health Canada does not approve 5-amino-1MQ as a therapeutic drug, natural health product, or over-the-counter medication.

5-amino-1MQ 10mg Canada is classified as an investigational research compound and is supplied strictly for laboratory and analytical use. It is not intended for human or veterinary administration.

Handling, storage, and research involving 5-amino-1MQ 10mg Canada must comply with applicable Canadian federal and provincial regulations governing chemical research materials. Laboratories and institutions are responsible for ensuring regulatory compliance.

Molecular and Structural Notes

5-amino-1MQ is a small-molecule quinolinium derivative with structural characteristics that enable interaction with the NNMT active site in experimental models. Its quaternary ammonium structure contributes to the enzyme binding affinity observed in laboratory studies.

The compound’s relatively low molecular weight, compared to peptide-based research compounds, allows it to be studied within small-molecule pharmacology frameworks. Analytical verification of 5-amino-1MQ 10mg Canada is typically conducted using high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and mass spectrometry to confirm identity and purity.

The crystalline olyophilized format supports stability when stored under appropriate laboratory conditions.

Frequently Asked Questions

What is 5-amino-1MQ 10mg Canada studied for in research?
5-amino-1MQ 10mg (Canada) is being studied in laboratory settings to investigate NNMT inhibition and metabolic pathway modulation.

Is 5-amino-1MQ approved for medical use in Canada?
No, Health Canada does not authorize it for therapeutic or consumer use.

What type of compound is 5-amino-1MQ?
It is a synthetic small-molecule compound studied as an NNMT inhibitor in metabolic research contexts.

Does 5-amino-1MQ 10mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the research-grade compound.

Can 5-amino-1MQ 10mg Canada be used outside of research environments?
No. It is supplied exclusively for laboratory and analytical research purposes.

Educational Disclaimer

5-amino-1MQ 10mg Canada is an investigational research compound supplied solely for laboratory and analytical use. Health Canada does not approve it as a medication, therapeutic agent, or consumer product.

The information provided on this page is educational and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of 5-amino-1MQ 10mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.